BridgeBio Pharma Inc
BBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.19B
Close$
$-76.74
205.9% downside
Current Fair Value
205.9% downsideOvervalued by 205.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14.19 Billion |
|---|---|
| Enterprise Value | $16.01 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.79 |
| Beta | 0.97 |
| Outstanding Shares | 195,785,884 |
Return
| Return on Equity | 27.68% |
|---|---|
| Return on Assets | -57.20% |
| Return on Invested Capital | -186.30% |
Valuation & Multiples
| P/E Ratio | -20.23 |
|---|---|
| PEG | 123.98 |
| Price to Sales | 24.15 |
| Price to Book Ratio | -5.57 |
| Enterprise Value to Revenue | 23.62 |
| Enterprise Value to EBIT | -26.31 |
| Enterprise Value to Net Income | -23 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | -0.99 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
$220.91 M
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$-0.67
Average shareholder expectationRevenue Estimate
$269.88 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1652▲ 1.48% |
|---|---|
| Total Calls | 11,050,000▲ 6.51% |
| Total Puts | 1,825,800▲ 17.02% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 106.10%▲ 6.16% |
|---|---|
| Total Invested | $14.70B▲ 1.93% |
| Investors Holding | 512▲ 17.00% |
ESG Score
No data
About BridgeBio Pharma Inc
CEO: Neil Kumar